Teladoc Health Inc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 9B. Other Information
(a) Effective February 27, 2025, we amended our 2023 Employment Inducement Incentive Award Plan (as amended, the “2023 Inducement Plan”) solely to increase the number of shares of common stock, par value $0.001 per share (“Common Stock”), reserved for issuance under the 2023 Inducement Plan by 1,000,000 shares, to a new total of
5,500,000 shares of Common Stock. The amendment is filed as Exhibit 10.25 hereto and incorporated herein by reference. As previously disclosed, the 2023 Inducement Plan was adopted by our Board without stockholder approval pursuant to NYSE Rule 303A.08.
(b)Rule 10b5-1 Trading Plans. During the three months ended December 31, 2023, the following officer (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934) adopted a Rule 10b5-1 trading arrangement (as defined in Item 408 of Regulation S-K of the Securities Act of 1933), which was intended to satisfy the affirmative defense of Rule10b5-1(c):
On November 18, 2024, Fernando Madeira Rodrigues, our President of BetterHelp, adopted a Rule 10b5-1 trading plan, which was amended on November 27, 2024, that provides for the sale of up to 36,540 shares of our common stock through December 2025.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.